377 related articles for article (PubMed ID: 24165155)
1. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
2. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
Björkman S
Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
[TBL] [Abstract][Full Text] [Related]
4. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
5. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
Björkman S
Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
Chang HH; Yang YL; Hung MH; Tsay W; Shen MC
J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
[TBL] [Abstract][Full Text] [Related]
9. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
Suzuki A; Tomono Y; Korth-Bradley JM
Haemophilia; 2016 Sep; 22(5):e359-66. PubMed ID: 27353956
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
12. Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B.
Brennan Y; Curnow J; Favaloro EJ
Expert Opin Biol Ther; 2018 Jan; 18(1):95-100. PubMed ID: 29172774
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
14. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
15. FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.
Perrier-Cornet A; Philippe A; Lambert T; d'Oiron R; Rafowicz A; Lavenu-Bombled C; Combe S; Gillibert A; Proulle V
Haemophilia; 2019 Nov; 25(6):e361-e363. PubMed ID: 31206947
[No Abstract] [Full Text] [Related]
16. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
17. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
[TBL] [Abstract][Full Text] [Related]
18. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
[TBL] [Abstract][Full Text] [Related]
19. The future of recombinant coagulation factors.
Saenko EL; Ananyeva NM; Shima M; Hauser CA; Pipe SW
J Thromb Haemost; 2003 May; 1(5):922-30. PubMed ID: 12871357
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]